Replies to post #392041 on Amarin Corp Plc (AMRN)

[ziploc_1]

I would rather have Amarin drop Vascepa entirely and just market the patented MND-2119, plus a fixed dose combo with a statin plus MND-2119.

[Birdbrain Ideas]

That was very interesting that KM said on the earnings call yesterday that the company was ready to leap into the U.S. market with its own generic if the conditions changed in a way that would warrant such a move.

I'm guessing that Amarin will launch a generic if generics capture 50 percent or more of the market. At that point, it might be more profitable to operate as a generic. Another catalyst might be if one or more of the companies that have agreed to use brand Vascepa exclusively changes its mind.